The San Diego oncology biotech targeting virus-associated cancers that raised $175M and wound down in 2023 after its lead program failed in clinical trials
Evaluating only Viracta Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
MILESTONE
FUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Viracta Therapeutics targeted cancers driven by the Epstein-Barr virus — a genuinely underserved area of oncology where EBV-positive lymphomas had few treatment options. They raised $175M through their IPO and follow-on offerings and built a small molecule approach to reactivating latent EBV in tumor cells. The science was novel. But their lead program nanatinostat failed to show adequate efficacy in clinical trials, and the company announced a full wind-down of operations in late 2023. Another biotech that had the right target but the wrong drug to hit it.
Lesson
“Oncology IPOs in low-rate environments raise capital on mechanism novelty before efficacy is proven — when rates rise and capital becomes selective, the clinical bar rises too.”